Compare Adaptive Biotechnologies Corp (ADPT) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs KB Financial Group, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while KB Financial Group, Inc. trades at $115.25 (market cap $39.97B). The key difference: KB Financial Group, Inc. is far larger — about 12× Adaptive Biotechnologies Corp's market cap, and KB Financial Group, Inc. pays a 2.72% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KB | |
|---|---|---|
Market Cap | $3.33B | $39.97B |
Sector | Health | Financials |
52-Week High | $22.37 | $118.21 |
52-Week Low | $10.24 | $77.50 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
KB trades at $115.48, up 5.61% today, showing strong momentum near its 52-week high. Recent quarters have consistently beaten earnings expectations, with Q1 2026 EPS of $3.49 surpassing estimates. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust revenue growth to $21.23T in 2025 and a healthy net income margin of 27.82%.
Outlook remains positive given earnings beats and valuation appeal with a P/E of 10.95, though risks include volatile cash flows and high interest expenses. Analyst sentiment is mixed with 33% buy ratings, suggesting cautious optimism for continued performance if execution aligns with growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
